Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions—United States
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: The 13-valent pneumococcal vaccine (PCV13) was introduced for US children in 2010 and for immunocompromised adults ≥19 years old in series with the 23-valent polysaccharide vaccine (PPSV23) in 2012. We evaluated PCV13 indirect effects on invasive pneumococcal disease (IPD) among adults with and without PCV13 indications. Methods: Using Active Bacterial Core surveillance and the National Health Survey, using Active Bacterial Core surveillance and the National Health Interview Survey, we estimated and compared IPD incidence in 2013–2014 and 2007–2008, by age and serotype group (PCV13, PPSV23-unique, or nonvaccine types [NVTs]), among adults with and without PCV13 indications. Results: IPD incidence declined among all adults. Among adults 19–64 years, PCV13-type IPD declined 57% (95% confidence interval [CI], −68% to −43%) in adults with immunocompromising conditions (indication for PCV13 use), 57% (95% CI, −62% to –52%) in immunocompetent adults with chronic medical conditions (CMCs, indications for PPSV23 use alone), and 74% (95% CI, −78% to −70%) in adults with neither vaccine indication. Among adults aged ≥65 years, PCV13-type IPD decreased 68% (95% CI, −76% to −60%) in those with immunocompromising conditions, 68% (95% CI, −72% to −63%) in those with CMCs, and 71% (95% CI, −77% to −64%) in healthy adults. PPSV23-unique types increased in adults 19‒64 years with CMCs, and NVTs did not change among adults with or without PCV13 indications. From 2013 to 2014, non-PCV13 serotypes accounted for 80% of IPD. Conclusions: IPD incidence among US adults declined after PCV13 introduction in children. Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest that observed benefits are largely due to indirect effects from pediatric PCV13 use rather than direct use among adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
Bonten, M. J. M., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C. H., van Deursen, A. M. M., Sanders, E. A. M., Verheij, T. J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408544 · Cited by 1,248
Waight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70044-7 · Cited by 589
Cited by
Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., & Pilishvili, T. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6846a5 · Cited by 668
Self-citationSurveillance of Vaccination Coverage Among Adult Populations —United States, 2018
Lu, P.-J., Hung, M.-C., Srivastav, A., Grohskopf, L. A., Kobayashi, M., Harris, A. M., Dooling, K. L., Markowitz, L. E., Rodriguez-Lainz, A., & Williams, W. W. (2021) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7003a1 · Cited by 346
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Who should be prioritised for COVID-19 vaccination?
Russell, F. M., & Greenwood, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1827882 · Cited by 75
“Herd protection has been demonstrated in varying degrees for a number of vaccines including the pneumococcal conjugate vaccine, with vaccination of young children (the age group most responsible for transmitting pneumococci) protecting the elderly from pneumococcal disease through indirect effects.(6) Deciding how muc…”
BackgroundThe Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children
Kao, C. M., Orenstein, W. A., & Anderson, E. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa712 · Cited by 56
Metadata
- Authors
- Ahmed, S. S., Pondo, T., Xing, W., McGee, L., Farley, M., Schaffner, W., Thomas, A., Reingold, A., Harrison, L. H., Lynfield, R., Rowlands, J., Bennett, N., Petit, S., Barnes, M., Smelser, C., Beall, B., Whitney, C. G., & Pilishvili, T.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-12
- Volume
- 70
- Issue
- 12
- Pages
- 2484-2492
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2968027080
- Cited by
- 79
- References
- 2
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions—United States. https://app.cochat.ai/papers/10.1093/cid/ciz739
- The paper
- Ahmed, S. S., Pondo, T., Xing, W., McGee, L., Farley, M., Schaffner, W., Thomas, A., Reingold, A., Harrison, L. H., Lynfield, R., Rowlands, J., Bennett, N., Petit, S., Barnes, M., Smelser, C., Beall, B., Whitney, C. G., & Pilishvili, T. (2020). Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions—United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.